Table 10.
Distribution of Histologically-Confirmed Brain and Other Central Nervous System Tumors by WHO Grade, Treatment Information Completeness, and Major Histology Grouping, CBTRUS Statistical Report: NPCR and SEER, 2011-2015
| Histology | Number of Newly Diagnosed Tumors (2011-2015) | Histologically Confirmed (%) | WHO Grade Completeness (%) | Assigned WHO Grade | Radiation Information Completeness b (%) | Surgical Extent of Resection Information Completeness c (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete a | Incomplete | Not Applicable | Grade I | Grade II | Grade III | Grade IV | |||||
| Tumors of Neuroepithelial Tissue | 110,861 | 89.3% | 84.1% | 14.4% | 1.5% | 10.7% | 14.4% | 13.7% | 61.1% | 49.1% | 98.1% |
| Pilocytic astrocytoma | 5,212 | 91.9% | 85.8% | 13.9% | 0.4% | 92.8% | 6.0% | 0.8% | 0.4% | 6.0% | 99.1% |
| Diffuse astrocytoma | 7,562 | 92.3% | 84.7% | 15.2% | 0.1% | 3.7% | 61.5% | 21.0% | 13.8% | 44.5% | 98.0% |
| Anaplastic astrocytoma | 6,797 | 99.3% | 94.2% | 5.7% | 0.1% | 0.1% | 1.2% | 90.1% | 8.6% | 70.1% | 99.3% |
| Unique astrocytoma variants | 1,161 | 76.3% | 74.9% | 24.8% | 0.2% | 22.9% | 55.1% | 16.9% | 5.1% | 18.2% | 98.1% |
| Malignant | 790 | 87.2% | 77.1% | 22.8% | 0.1% | 4.0% | 68.5% | 21.1% | 6.4% | 26.3% | 98.0% |
| Non-Malignant | 371 | 53.1% | 67.5% | 32.0% | 0.5% | 98.5% | 1.5% | 0.0% | 0.0% | 0.8% | 98.4% |
| Glioblastoma | 57,805 | 93.1% | 86.8% | 13.2% | 0.0% | 0.2% | 0.2% | 0.8% | 98.8% | 62.2% | 97.9% |
| Oligodendroglioma | 3,679 | 96.4% | 92.6% | 7.4% | 0.1% | 1.5% | 86.0% | 6.8% | 5.7% | 25.7% | 98.5% |
| Anaplastic oligodendroglioma | 1,767 | 99.2% | 95.1% | 4.9% | 0.0% | 0.1% | 2.8% | 88.4% | 8.6% | 62.8% | 98.7% |
| Oligoastrocytic tumors | 2,651 | 99.5% | 95.1% | 4.9% | 0.0% | 0.8% | 51.1% | 39.9% | 8.1% | 49.6% | 99.5% |
| Ependymal tumors | 6,858 | 90.1% | 84.2% | 15.8% | 0.0% | 35.3% | 49.8% | 14.1% | 0.7% | 23.7% | 98.5% |
| Malignant | 4,045 | 94.0% | 87.7% | 12.3% | 0.1% | 2.7% | 74.3% | 22.0% | 1.1% | 34.3% | 98.4% |
| Non-Malignant | 2,813 | 84.4% | 78.5% | 21.5% | 0.0% | 93.8% | 6.0% | 0.1% | 0.1% | 8.4% | 98.6% |
| Glioma malignant, NOS | 7,518 | 32.6% | 44.4% | 54.7% | 0.9% | 20.7% | 28.6% | 24.2% | 26.6% | 23.8% | 97.8% |
| Choroid plexus tumors | 820 | 88.3% | 73.6% | 26.4% | 0.0% | 66.0% | 17.1% | 16.3% | 0.6% | 4.9% | 98.1% |
| Malignant | 129 | 97.7% | 81.0% | 19.0% | 0.0% | 7.8% | 3.9% | 85.3% | 2.9% | 18.6% | 100.0% |
| Non-Malignant | 691 | 86.5% | 72.1% | 27.9% | 0.0% | 79.8% | 20.2% | 0.0% | 0.0% | 2.3% | 97.8% |
| Other neuroepithelial tumors | 100 | 96.0% | 46.9% | 52.1% | 1.0% | 6.7% | 53.3% | 24.4% | 15.6% | 36.0% | 100.0% |
| Malignant | 66 | 100.0% | 36.4% | 62.1% | 1.5% | 4.2% | 20.8% | 45.8% | 29.2% | 47.0% | 100.0% |
| Non-Malignant | 34 | 88.2% | 70.0% | 30.0% | 0.0% | 9.5% | 90.5% | 0.0% | 0.0% | 14.7% | 100.0% |
| Neuronal and mixed neuronal-glial tumors | 4,640 | 93.4% | 61.7% | 21.1% | 17.2% | 79.9% | 15.6% | 3.8% | 0.8% | 14.1% | 98.6% |
| Malignant | 922 | 98.6% | 15.1% | 5.6% | 79.3% | 19.7% | 6.6% | 62.8% | 10.9% | 54.2% | 97.7% |
| Non-Malignant | 3,718 | 92.1% | 74.1% | 25.2% | 0.7% | 83.1% | 16.0% | 0.6% | 0.2% | 4.1% | 98.8% |
| Tumors of the pineal region | 767 | 75.7% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 35.9% | 97.5% |
| Malignant | 422 | 95.0% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 56.4% | 99.1% |
| Non-Malignant | 345 | 52.2% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 10.7% | 96.3% |
| Embryonal tumors | 3,524 | 98.1% | 73.2% | 25.9% | 0.9% | 1.2% | 0.2% | 1.5% | 97.1% | 56.7% | 97.5% |
| Tumors of Cranial and Spinal Nerves | 33,771 | 51.2% | 31.0% | 69.0% | 0.0% | 99.0% | 0.5% | 0.3% | 0.2% | 17.1% | 98.3% |
| Nerve sheath tumors | 33,738 | 51.2% | 31.0% | 69.0% | 0.0% | 99.0% | 0.5% | 0.3% | 0.2% | 17.1% | 98.3% |
| Malignant | 225 | 82.7% | 18.8% | 81.2% | 0.0% | 48.6% | 11.4% | 28.6% | 11.4% | 32.4% | 81.7% |
| Non-Malignant | 33,513 | 51.0% | 31.2% | 68.8% | 0.0% | 99.3% | 0.4% | 0.1% | 0.1% | 17.0% | 98.4% |
| Other tumors of cranial and spinal nerves | 33 | 39.4% | 30.8% | 69.2% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% | 3.0% | 100.0% |
| Tumors of Meninges | 150,390 | 42.5% | 75.5% | 24.4% | 0.1% | 80.4% | 17.4% | 2.1% | 0.1% | 6.8% | 97.9% |
| Meningioma | 145,916 | 41.2% | 77.1% | 22.9% | 0.0% | 80.6% | 17.6% | 1.7% | 0.1% | 6.5% | 97.9% |
| Malignant | 1,771 | 79.2% | 82.9% | 17.1% | 0.0% | 23.0% | 16.1% | 59.7% | 1.2% | 30.3% | 85.1% |
| Non-Malignant | 144,145 | 40.8% | 77.0% | 23.0% | 0.0% | 82.1% | 17.6% | 0.2% | 0.1% | 6.3% | 98.0% |
| Mesenchymal tumors | 1,385 | 71.8% | 49.9% | 48.9% | 1.1% | 6.4% | 50.7% | 38.4% | 4.4% | 27.1% | 98.4% |
| Primary melanocytic lesions | 123 | 91.1% | 10.7% | 86.6% | 2.7% | 66.7% | 16.7% | 8.3% | 8.3% | 36.6% | 94.2% |
| Other neoplasms related to the meninges | 2,966 | 91.7% | 51.9% | 46.7% | 1.4% | 99.2% | 0.6% | 0.1% | 0.2% | 6.8% | 98.7% |
| Lymphomas and Hematopoietic Neoplasms | 7,818 | 94.0% | 10.6% | 87.7% | 1.7% | 100.0% | 0.0% | 0.0% | 0.0% | 21.4% | 99.1% |
| Lymphoma | 7,585 | 94.1% | 11.1% | 88.0% | 0.9% | 100.0% | 0.0% | 0.0% | 0.0% | 21.1% | 99.1% |
| Other hematopoietic neoplasms | 233 | 90.6% | 0.7% | 82.1% | 17.2% | 100.0% | 0.0% | 0.0% | 0.0% | 31.8% | 99.2% |
| Germ Cell Tumors and Cysts | 1,487 | 81.9% | 1.8% | 55.6% | 42.6% | 18.2% | 9.1% | 4.5% | 68.2% | 43.1% | 99.0% |
| Germ cell tumors, cysts and heterotopias | 1,487 | 81.9% | 1.8% | 55.6% | 42.6% | 18.2% | 9.1% | 4.5% | 68.2% | 43.1% | 99.0% |
| Malignant | 1,004 | 88.7% | 2.1% | 43.1% | 54.7% | 5.3% | 10.5% | 5.3% | 78.9% | 62.8% | 99.1% |
| Non-Malignant | 483 | 67.7% | 0.9% | 89.6% | 9.5% | 100.0% | 0.0% | 0.0% | 0.0% | 2.1% | 98.9% |
| Tumors of Sellar Region | 67,765 | 50.0% | 0.5% | 0.6% | 98.9% | 99.4% | 0.0% | 0.6% | 0.0% | 3.1% | 98.0% |
| Tumors of the pituitary | 64,749 | 48.4% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 2.3% | 98.0% |
| Malignant | 175 | 66.3% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 16.6% | 88.2% |
| Non-Malignant | 64,574 | 48.4% | 0.0% | 0.0% | 100.0% | -- | -- | -- | -- | 2.3% | 98.0% |
| Craniopharyngioma | 3,016 | 83.9% | 6.1% | 8.6% | 85.3% | 99.4% | 0.0% | 0.6% | 0.0% | 20.2% | 98.1% |
| Unclassified Tumors | 20,890 | 17.5% | 4.3% | 87.1% | 8.6% | 64.1% | 7.7% | 11.5% | 16.7% | 2.7% | 71.1% |
| Hemangioma | 6,182 | 29.0% | 2.5% | 97.1% | 0.4% | 93.3% | 2.2% | 2.2% | 2.2% | 1.8% | 98.1% |
| Neoplasm, unspecified | 14,588 | 12.5% | 5.8% | 78.0% | 16.2% | 52.8% | 10.4% | 14.2% | 22.6% | 2.9% | 61.1% |
| Malignant | 6,679 | 8.7% | 8.1% | 84.8% | 7.1% | 14.9% | 10.6% | 27.7% | 46.8% | 4.0% | 43.7% |
| Non-Malignant | 7,909 | 15.7% | 4.8% | 74.8% | 20.5% | 83.1% | 10.2% | 3.4% | 3.4% | 2.0% | 76.2% |
| All other | 120 | 40.0% | 10.4% | 62.5% | 27.1% | 40.0% | 0.0% | 40.0% | 20.0% | 10.8% | 91.7% |
| TOTAL c | 392,982 | 57.6% | 62.0% | 21.8% | 16.2% | 39.0% | 14.9% | 9.1% | 37.1% | 19.2% | 96.1% |
| Malignant | 121,277 | 85.3% | 81.0% | 17.0% | 2.0% | 6.5% | 14.5% | 15.3% | 63.7% | 47.4% | 92.7% |
| Non-Malignant | 271,705 | 45.3% | 46.8% | 25.6% | 27.6% | 84.3% | 15.3% | 0.3% | 0.1% | 6.6% | 97.2% |
aCompleteness is defined as having an assigned code that corresponds with a WHO grade as defined by the American Joint Commission on Cancer’s Collaborative Staging schema.
bRadiation is defined using a recoded variable based on NAACCR Item #1360 (http://datadictionary.naaccr.org/default.aspx?c=10#136). Completeness is defined as having a value other than “none” or “unknown.”
cSurgery is defined using a recoded variable based on NAACCR Item #1290 (http://datadictionary.naaccr.org/default.aspx?c=10#1290). Please see the SEER site-specific surgery codes for more information on coding for this variable (https://seer.cancer.gov/archive/tools/SEER2003.surg.prim.site.codes.pdf). Completeness is defined as having a value other than “unknown.”
- Percentages are not presented when category is not applicable.
Abbreviations: CBTRUS, Central Brain Tumor Registry of the United States; CNS, central nervous system; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; WHO, World Health Organization